Floatz logo

LEVODOPA

Drug-Induced Dyskinesia

Sumitomo Pharma Co., Ltd.Small moleculePhase 4 / ApprovedActive
A
80/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Drug-Induced Dyskinesia cohort.

Asset / SponsorPhaseRating
carbidopa
AbbVie (prior sponsor, Abbott)
Phase 4BBB
Amantadine
Adamas Pharmaceuticals, Inc.
Phase 3BBB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BBB
Emd 128130
EMD Serono
Phase 3BBB
Eicosapentanoic Acid
University of Stellenbosch
Phase 4BB

View all 25 →

Same molecule, other indications

LEVODOPA is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
movement disorderDormant
BBB
Indicative ·
74 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →